Preconditioning with cobalt chloride or desferrioxamine protects oligodendrocyte cell line (MO3.13) from tumor necrosis factor-α-mediated cell death

Journal of Neuroscience Research

Volumn 86, Issue 11, 2008, Pages 2403-2413

  Yao, Song Yi ^a   Soutto, Mohammed ^a   Sriram, Subramaniam ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; HIF 1; Multiple sclerosis; Oligodendrocytes; Preconditioning; TNF

Indexed keywords

BETA ACTIN; CASPASE 3; COBALT CHLORIDE; DEFEROXAMINE; FRUCTOSE BISPHOSPHATE ALDOLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBITOR OF APOPTOSIS PROTEIN 2; OXYGEN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; CELL CULTURE; CELL DEATH; CELL ENERGY; CELL LINE; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; OXYGEN SUPPLY; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN STABILITY;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE; COBALT; DEFEROXAMINE; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICROSCOPY, FLUORESCENCE; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49349106109     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21697     Document Type: Article

References (54)

1. Andrews T, Zhang P, Bhat NR. 1998. TNFalpha potentiates IFN-gamma-induced cell death in oligodendrocyte progenitors. J Neurosci Res 54:574-583.
2. Bruck W, Stadelmann C. 2005. The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol 18:221-224.
3. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. 2000. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741.
4. Compston A. 2006. Making progress on the natural history of multiple sclerosis. Brain 129:561-563.
5. Confavreux C, Vukusic S, Moreau T, Adeleine P. 2000. Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430-1438.
6. Cramer T, Johnson RS. 2003. A novel role for the hypoxia inducible transcription factor HIF-1alpha: critical regulation of inflammatory cell function. Cell Cycle 2:192-193.
7. Dery MA, Michaud MD, Richard DE. 2005. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37:535-540.
8. Dong Z, Nishiyama J, Yi X, Venkatachalam MA, Denton M, Gu S, Li S, Qiang M. 2002. Gene promoter of apoptosis inhibitory protein IAP2: identification of enhancer elements and activation by severe hypoxia. Biochem J 364:413-421.
9. Dong Z, Wang JZ, Yu F, Venkatachalam MA. 2003. Apoptosis-resistance of hypoxic cells: multiple factors involved and a role for IAP-2. Am J Pathol 163:663-671.
10. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. 2002. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22:RC216.
11. Freeman RS, Barone MC. 2005. Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders. Curr Drug Targets CNS Neurol Disord 4:85-92.
12. Frohman EM. 2003. Multiple sclerosis. Med Clin North Am 87:867-897, viii-ix.
13. Frohman EM, Racke MK, Raine CS. 2006. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 354:942-955.
14. Ghezzi P, Brines M. 2004. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11(Suppl 1):S37-S44.
15. Gidday JM. 2006. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7:437-448.
16. Ginis I, Jaiswal R, Klimanis D, Liu J, Greenspon J, Hallenbeck JM. 2002. TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: the role of NF-kappaB association with p300 adaptor. J Cereb Blood Flow Metab 22:142-152.
17. Goda N, Dozier SJ, Johnson RS. 2003. HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antiox Redox Signal 5:467-473.
18. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. 2003. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13:554-573.
19. Greijer AE, van der Wall E. 2004. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57:1009-1014.
20. Haddad JJ, Harb HL. 2005. Cytokines and the regulation of hypoxia-inducible factor (HIF)-1alpha. Int Immunopharmacol 5:461-483.
21. Hammond EM, Giaccia AJ. 2005. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331:718-725.
22. Harris AL. 2002. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
23. Hawaleshka A, Jacobsohn E. 1998. Ischaemic preconditioning: mechanisms and potential clinical applications. Can J Anaesth 45:670-682.
24. Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W. 2005. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res 25:297-310.
25. Hovelmeyer N, Hao Z, Kranidioti K, Kassiotis G, Buch T, Frommer F, von Hoch L, Kramer D, Minichiello L, Kollias G, Lassmann H, Waisman A. 2005. Apoptosis of oligodencrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J Immunol 175:5875-5884.
26. 2-regulated prolyl hydroxylation. Science 292:468-472.
27. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L. 2003. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J 370:1011-1017.
28. Jurewicz A, Matysiak M, Tybor K, Kilianek L, Raine CS, Selmaj K. 2005. Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor [10.1093/brain/awh627]. Brain 128:2675-2688.
29. Kastrup O, Stude P, Limmroth V. 2001. Balo's concentric sclerosis demonstrated by contrast MRI. Neurology 57:1610.
30. Love S. 2005. Establishing preconditions for Balo's concentric sclerosis. Brain 128:960-962.
31. Lu GW, Yu S, Li RH, Cui XY, Gao CY. 2005. Hypoxic preconditioning: a novel intrinsic cytoprotective strategy. Mol Neurobiol 31:255-271.
32. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717.
33. Maggs FG, Palace J. 2004. The pathogenesis of multiple sclerosis: is it really a primary inflammatory process? Mult Scler 10:326-329.
34. McLaurin J, Trudel GC, Shaw IT, Antel JP, Cashman NR. 1995. A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J Neurobiol 26:283-293.
35. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N Engl J Med 343:938-946.
36. O'Duffy AE, Bordelon YM, McLaughlin B. 2006.Killer proteases and little strokes - how the things that do not kill you make you stronger.
37. Pong K. 2004. Ischaemic preconditioning: therapeutic implications for stroke? Expert Opin Ther Targets 8:125-139.
38. Rudick RA, Cutter GR, Baier M, Weinstock-Guttman B, Mass MK, Fisher E, Miller DM, Sandrock AW. 2005. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 11:626-634.
39. Ruffini F, Chojnacki A, Weiss S, Antel JP. 2006. Immunobiology of oligodendrocytes in multiple sclerosis. Adv Neurol 98:47-63.
40. Selmaj K, Rame CS, Farooq M, Brosnan C. 1991. Cytokine cytotoxicity against oligodendrocytes: Apoptosis induced by lymphotoxin. J Immunol 147:1522-1530.
41. Semenza GL. 2001. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7:345-350.
42. Semenza GL. 2004. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 19:176-182.
43. Semenza GL. 2006. Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets 10:267-280.
44. Sharp FR, Ran R, Lu A, Tang Y, Strauss KI, Glass T, Ardizzone T, Bernaudin M. 2004. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx 1:26-35.
45. Shohand E, Ginis I, Hallenbeck JM. 1999. Dual rote of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 10:119-130.
46. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, Ratan RR. 2005a. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the CNS. J Biol Chem 280:41732-41743.
47. Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF, Leel-Ossy L, Ordinario AT, Bruck W, Lassmann H. 2005. Tissue preconditioning may explain concentric lesions in Bale's type of multiple sclerosis. Brain 128:979-987.
48. Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E. 2000. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 350:307-312.
49. Vartanian T, Li Y, Zhao M, Stefansson K. 1995. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med 1:732-743.
50. Wajant H, Pfizenmaier K, Scheurich P. 2003. Tumor necrosis factor signaling. Cell Death Differ 10:45-65.
51. Watts TH. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23-68.
52. Zajisek JP, Wing MG, Scolding N, Compston DAS. 1992. Interaction between oligodendrocyte and microglia: a major role for complementin oligodendrocyte adherence and killing. Brain 115:1611-1631.
53. Zarember KA, Malech HL. 2005. HIF-lalpha: a master regulator of innate host defenses? J Clin Invest 115:1702-1704.
54. Zhou J, Schmid T, Brune B. 2003. Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1alpha through a nuclear factor-kappaB-dependent pathway. Mol Biol Cell 14:2216-2225.